Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 6/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275539 | 1.00 | CTSK (0.43) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL7116478 | 1.00 | CTSK (0.43) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL7743860 | 0.89 | CTSK (0.49) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL7275058 | 0.86 | CTSK (0.42) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL17903255 | 0.86 | CTSK (0.42) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL6684772 | 0.85 | CA1 (0.49) | CTSKCA1CA2CA7ATM | |
| SCHEMBL211054 | 0.84 | CTSK (0.45) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL5196572 | 0.84 | CTSK (0.45) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL211053 | 0.84 | CTSK (0.45) | CTSKMAPTCA1CA2CA7 | |
| SCHEMBL12290180 | 0.84 | CTSK (0.45) | CTSKMAPTCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-112041313-A | Pyridine-sulfonamide compounds and their use against pain and related conditions | 基因泰克公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| WO-2019165290-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | GENENTECH, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| EP-3037424-B1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-9758526-B2 | Quinoline-substituted compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9650386-B2 | Quinoline-substituted compound | Taiho Pharmaceutical Co., Inc. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-20170101414-A1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-04-13 | — | — | US | disclosed |
| US-20160194332-A1 | NOVEL QUINOLINE -SUBSTITUTED COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-3037424-A1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | CTSK 579/4885MAPT 1547/4885CA1 326/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | CTSK 2607/4885MAPT 3785/4885CA1 589/4885 |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | CTSK 2360/4885MAPT 3593/4885CA1 1419/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | CTSK 2360/4885MAPT 3593/4885CA1 1419/4885 |
| US-20170101414-A1 | NOVEL QUINOLINE-SUBSTITUTED COMPOUND | EGFR, ERBB2, ERBB4 | CTSK 1735/4885MAPT 4330/4885CA1 4015/4885 |
| US-20160194332-A1 | NOVEL QUINOLINE -SUBSTITUTED COMPOUND | EGFR, ERBB2, ERBB4 | CTSK 1735/4885MAPT 4330/4885CA1 4015/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | CTSK 2607/4885MAPT 3785/4885CA1 589/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | CTSK 2350/4885MAPT 3628/4885CA1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.